In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bio-Rad Buys Sanofi Dx

Executive Summary

Bio-Rad Laboratories is buying Sanofi Diagnostics from Sanofi-Synthelabo in order to increase its mass, goegraphical scope, and diversity of product lines. Bio-Rad, which has life sciences and analytical instruments businesses in addition to a clinical diagnostics business, makes a number of assays and it is looking to increase its presence in infectious diseases, where Sanofi is strong. Sanofi makes tests for infectious diseases and is strong in HIV diagnostics. Burt does Bio-Rad have the wherewithall to make this deal work, given the two companies differ in culture and strengths?
Advertisement
Advertisement

Related Content

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV001232

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel